Heaptalk, Jakarta — Singapore-based health deep tech startup transforming chronic disease management system, Mesh Bio, has secured undisclosed funding from East Ventures. The funding will be allocated to develop digital twin technologies in chronic disease management and to expand its services across Southeast Asia, particularly Indonesia, Malaysia, and the Philippines.
Prior to seizing this new undisclosed funding round, this health tech startup also gained seed investment worth US$1.8 million in 2021. Several deep tech investors, including Elev8.vc and Enterprise Singapore arm SEEDS Capital, led this round, with participation from Crine Capital and TAEL Partners.
The Co-Founder and Chief Executive Officer, Dr. Andrew Wu, revealed, “Given the increasing aging population worldwide, Mesh Bio has consistently prioritized the development of innovative solutions to alleviate healthcare challenges associated with chronic diseases. We are glad to receive the support from East Ventures, and we are confident that this funding will serve as a strong foundation in our vision to confront the rising burden of chronic diseases across the regions,”
Established in 2018, Mesh Bio has the vision to deliver cutting-edge digital solutions to address challenges in patient management and rising diseases in the region. The company observed that Noncommunicable Diseases (NCDs), commonly known as chronic diseases, including cardiovascular diseases and diabetes, impose a significant and growing burden on health and development in Southeast Asia. According to the data, around 62% of all deaths are due to NCDs, accounting for 9 million people in the region.
Moreover, the company perceived that chronic diseases complicate patient management due to several obstacles, such as needing doctors, especially specialists. This obstacle also impacts general practitioners who need more specialist training in endocrinology and are forced to treat chronic patient cases.
For this reason, this health tech startup provides digital solutions to address challenges in patient management and rising chronic diseases in the regions. Mesh Bio’s Health Intelligence Platform DARA® grants real-time, multidimensional patient data, which includes health history, lab tests, and medical images. This platform delivers a patient-centric visual report, helping doctors counsel patients and allowing them to comprehend their laboratory reports and diseases.
According to the data, this health intelligence system offers predictive analytics to identify patients at risk of chronic diseases for earlier diagnosis and treatment. Moreover, the DARA platform also enables doctors to leverage knowledge from the global community of healthcare practitioners according to clinical best practices, guidelines, and holistic patient assessments.
“The startup approach could become one of the foundations to provide a better regional healthcare system. We believe that predictive analytics and preventive healthcare can benefit society greatly. Through its digital twin-engine, East Ventures looks forward to revolutionizing the healthcare sector,” the Co-Founder and Managing Partner at East Ventures, Willson Cuaca, affirmed.
